MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers
MiNK Therapeutics, Inc. (INKT)
Company Research
Source: GlobeNewswire
Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue participation NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT) a clinical-stage biopharmaceutical company advancing invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases, today announced a strategic collaboration with C-Further, an international pediatric oncology therapeutics consortium enabled by Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity (GOSH Charity), to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. This collaboration represents one of the first programs selected by C-Further since the consortium’s launch and reflects a shared commitment to accelerating innovative, well-tolerated immunotherapies for children with cancers that have limited treatment
Show less
Read more
Impact Snapshot
Event Time:
INKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INKT alerts
High impacting MiNK Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
INKT
News
- MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers [Yahoo! Finance]Yahoo! Finance
- C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology [Yahoo! Finance]Yahoo! Finance
- C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric OncologyBusiness Wire
- MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia [Yahoo! Finance]Yahoo! Finance
- MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone SymposiaGlobeNewswire
INKT
Earnings
- 11/14/25 - Beat
INKT
Sec Filings
- 3/11/26 - Form 4
- 3/4/26 - Form 4
- 1/14/26 - Form 4/A
- INKT's page on the SEC website